Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05718245 · ClinicalTrials.gov registry record · NA
HEPA, PM2.5, and Cardiometabolic Health
A NA study of Air Pollution and Cardiometabolic Health, sponsored by University of Southern California.
- Recruiting
- Registry status
- NA
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT05718245: Recruiting NA study of Air Pollution and Cardiometabolic Health, sponsored by University of Southern California.
NCT05718245 is a NA study of Air Pollution and Cardiometabolic Health that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 52 participants, roughly in line with the 55-participant average among 7 other Air Pollution trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05718245, a NA study of Air Pollution and Cardiometabolic Health, is actively recruiting participants, sponsored by University of Southern California.
- RECRUITING
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this randomized, double-blind, crossover trial is to test the hypothesis that a longer-term indoor HEPA filtration intervention can improve cardiometabolic profiles by reducing indoor PM2.5 exposures in at-risk individuals.
Primary Outcome
Difference between baseline and HOMA-IR measured after 6-month intervention
Conditions Studied
Interventions
- DEVICE HEPA filter
- DEVICE Sham filter
Study Locations (1)
California
- Keck School of Medicine, University of Southern California - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT05718245 shows while recruiting
NCT05718245 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, roughly in line with the 55-participant average among 7 other Air Pollution trials with a reported enrollment target.
The record links to 2 conditions, with Air Pollution appearing as the primary indexed condition, and to 2 interventions - of which HEPA filter is the first listed.
NCT05718245 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05718245 about?
NCT05718245 is a clinical study titled "HEPA, PM2.5, and Cardiometabolic Health". The goal of this randomized, double-blind, crossover trial is to test the hypothesis that a longer-term indoor HEPA filtration intervention can improve cardiometabolic profiles by reducing indoor PM2.5 exposures in at-risk individuals.
What is the current status of trial NCT05718245?
This trial is currently recruiting. It is a NA study. The enrollment target is 52 participants. The study started on 2023-03-15. Estimated completion is 2026-12-31.
What conditions does trial NCT05718245 study?
This clinical trial studies the following conditions: Air Pollution, Cardiometabolic Health.
What interventions are being tested in trial NCT05718245?
The interventions under investigation include: HEPA filter (DEVICE), Sham filter (DEVICE).
Who is sponsoring clinical trial NCT05718245?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05718245 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Air Pollution
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Role of Macrophage Activation in Lung Injury Following Ozone Exposure
RECRUITING · NA
-
Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History
RECRUITING · NA
-
Does Sildenafil Increase Exercise Performance in Air Pollution?
COMPLETED · NA
-
Particulate Matter, Blood Pressure, and the Sympathetic Nervous System
COMPLETED · NA
-
Boston Puerto Rican Health Study
COMPLETED · NA
-
Air Pollution: Strategies for Personalized Intervention to Reduce Exposure
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI